Melanotan II
Research OnlyA non-selective melanocortin receptor agonist known for tanning effects. Not approved by any regulatory agency; associated with significant safety concerns including melanoma risk and systemic toxicity.
MT-II · MT-2
8 human studies
- Preclinical
- 15%
- Clinical
- 31%
Based on 26 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 55: best human evidence is small double-blind placebo-controlled crossover trials, all n<50 (1A 25 — Wessells 1998 n=10 PMID 9679884, Wessells 2000 n=20 PMID 11035391, Dorr 1996 n=3 placebo-controlled phase I PMID 8637402); decent crossover design but small/no RCT systematic review (1B 12, "some concerns"); total controlled human N well under 50 (1C 3); direct population/route/outcome for tanning and erection (1D 10); modest MT-II-specific preclinical base (1E 5). Mechanism 85: named MC1R/MC4R targets with binding plus functional and class knockout/antagonist confirmation (2A 35); full MC1R->Gs->cAMP->PKA->MITF->tyrosinase melanogenesis chain and MC4R CNS pathway mapped (2B 26); dose-response in escalation trials and rat anorectic studies incl. in vivo (2C 14, PMID 12834882); confirmed in mammalian in vivo (2D 10). Plausibility 82: mechanism->surrogate->clinical outcome each supported in humans for tanning and erection (3A 33); fully coherent with melanocortin physiology and validated by approved class agents bremelanotide/setmelanotide (3B 24, 3C 18); but multi-system claims (tanning + sexual + appetite + CV) are moderately broad (3D 7). Global Coverage 61: replicated by independent groups across US/UK/Denmark/Bulgaria (4A 22, 4B 17), 20-100 study literature (4C 17), no regulatory approval anywhere — FDA Category 2 restriction only (4D 5). Community Experience 68: broad, persistent >7-year tanning-community use (5A 24, 5B 26) with consistent themes (5C 15), but a recurring serious adverse signal — melanoma, rhabdomyolysis, renal infarction, priapism — floors tolerability (5D 3). Effectiveness basis clinical (low confidence): objective tanning confirmed (Dorr 1996) and large erectogenic effect (17/20 men, ~38 vs 3 min tip rigidity, P=0.0045; Wessells 1998/2000) clearly exceed placebo, but evidence is small, dated, and never advanced past phase I/II.
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that binds non-selectively to melanocortin receptors MC1R, MC3R, MC4R, and MC5R. It was developed at the University of Arizona in the 1980s as a potential sunless tanning agent but was never approved due to safety concerns.
How It Works (Simplified)
Melanotan II acts as a “multi-target activator” affecting several body systems simultaneously:
Activates melanocytes to produce melanin pigment, causing skin darkening without UV exposure - bypassing the natural DNA-damage trigger.
Crosses blood-brain barrier to activate hypothalamic MC4R receptors, triggering dopamine release and spontaneous sexual arousal.
MC4R activation in hypothalamic appetite centers reduces hunger signaling, causing decreased food intake.
Melanocortin receptor activation causes pressor effects, raising blood pressure - a key safety concern noted in trials.
Key Research: Dorr RT et al. (Arizona, 1996) demonstrated tanning without UV exposure in the first human trial. PMID:8637402
Important Limitations
- Non-selective binding causes multiple unpredictable systemic effects
- Bypasses natural UV-triggered tanning surveillance mechanisms
- Associated with melanoma development in multiple case reports
- Never completed Phase 3 clinical trials
- Not approved by FDA, TGA, EMA, or any regulatory agency
- PT-141 (bremelanotide) was developed as a more selective alternative for sexual function
Reported positives
- Significant skin tanning without UV exposure
- Appetite suppression noted as side benefit
- Sexual enhancement effects reported by many users
- Long-lasting effects after loading phase
Reported negatives
- Nausea, especially with initial use
- New mole formation and darkening of existing moles concerning
- Facial flushing and headaches common
- Unregulated product quality raises safety concerns
“Very popular in tanning communities. Significant safety concerns led to FDA Category 2 restriction.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Initial administration may produce acute side effects including nausea, facial flushing, fatigue, and spontaneous erections. These effects are commonly reported from first dose and typically diminish with continued use.
PMID:8637402Early tanning effects may become visible, particularly with UV exposure. Freckles and existing moles may begin to darken. Appetite suppression and sexual effects often manifest during this period.
PMID:9679884Progressive skin darkening continues. Users report noticeable tan development. Mole changes may become more apparent. Side effects typically stabilize or diminish.
PMID:10816645Maximum tanning effect generally reached by 4-8 weeks. Some users transition to maintenance dosing. Long-term effects on moles and melanocyte activity remain concerning. No long-term safety data available.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
BPC-157
CautionBPC-157 has pro-angiogenic effects. Melanotan II stimulates melanocyte activity. Theoretical concern about combined effects on moles/nevi. No interaction studies available.
Semaglutide
CautionBoth can cause nausea. Melanotan II commonly causes GI effects. Monitor for additive adverse events.
Thymosin-Alpha-1
CautionBoth modulate immune function. Melanotan II's melanocortin effects may interact with immune signaling. Exercise caution.
GHK-Cu
CautionBoth may affect skin/pigmentation. GHK-Cu promotes wound healing while MT-II stimulates melanogenesis. Unknown if combined effects are safe for moles/nevi.
PT-141
AvoidPT-141 (bremelanotide) is derived from Melanotan II with more selective melanocortin receptor activity. Combining provides redundant stimulation with increased risk of adverse events.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Melanotan II
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.